Body mass index as a predictor of fracture risk: a meta-analysis

…, A Odén, H Johanson, O Johnell, P Delmas… - Osteoporosis …, 2005 - Springer
Low body mass index (BMI) is a well-documented risk factor for future fracture. The aim of
this study was to quantify this effect and to explore the association of BMI with fracture risk in …

Bone quality—the material and structural basis of bone strength and fragility

E Seeman, PD Delmas - New England journal of medicine, 2006 - Mass Medical Soc
This review discusses advances in knowledge regarding the composition and structure of
bone, the modeling and remodeling of bone, the formation of bone during growth and its …

The role of collagen in bone strength

S Viguet-Carrin, P Garnero, PD Delmas - Osteoporosis international, 2006 - Springer
Bone is a complex tissue of which the principal function is to resist mechanical forces and
fractures. Bone strength depends not only on the quantity of bone tissue but also on the quality…

[HTML][HTML] Vitamin D3 and Calcium to Prevent Hip Fractures in Elderly Women

…, J Brun, B Crouzet, S Arnaud, PD Delmas… - New England journal …, 1992 - Mass Medical Soc
… , the number of hip fractures was 43 percent lower (P = 0.043) and the total number of
nonvertebral fractures was 32 percent lower (P = 0.015) among the women treated with vitamin D …

[HTML][HTML] Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

DM Black, PD Delmas, R Eastell, IR Reid… - … England Journal of …, 2007 - Mass Medical Soc
Background A single infusion of intravenous zoledronic acid decreases bone turnover and
improves bone density at 12 months in postmenopausal women with osteoporosis. We …

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial

…, T Nickelsen, HK Genant, C Christiansen, PD Delmas… - Jama, 1999 - jamanetwork.com
… We report all categories of adverse events for which frequency was different (P<.05) between
the placebo and combined raloxifene groups and for which the incidence was at least 2% …

[HTML][HTML] Denosumab for prevention of fractures in postmenopausal women with osteoporosis

…, ES Siris, R Eastell, IR Reid, P Delmas… - … England Journal of …, 2009 - Mass Medical Soc
Background Denosumab is a fully human monoclonal antibody to the receptor activator of
nuclear factor-κB ligand (RANKL) that blocks its binding to RANK, inhibiting the development …

A meta-analysis of previous fracture and subsequent fracture risk

…, A Odén, P Delmas, J Eisman, S Fujiwara, P Garnero… - Bone, 2004 - Elsevier
Previous fracture is a well-documented risk factor for future fracture. The aim of this study was
to quantify this risk on an international basis and to explore the relationship of this risk with …

Predictive value of BMD for hip and other fractures

…, H Johansson, C De Laet, P Delmas… - Journal of bone and …, 2005 - academic.oup.com
The relationship between BMD and fracture risk was estimated in a meta‐analysis of data
from 12 cohort studies of ∼39,000 men and women. Low hip BMD was an important predictor …

[HTML][HTML] Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

PD Delmas, NH Bjarnason, BH Mitlak… - … England Journal of …, 1997 - Mass Medical Soc
Background Long-term estrogen therapy can reduce the risk of osteoporotic fracture and
cardiovascular disease in postmenopausal women. At present, however, these beneficial …